TRT and Sleep Apnea: Risk, Evidence, and How It Is Monitored

The short answer on TRT and sleep apnea

TRT and sleep apnea have an evidence-based but unsettled relationship. High-quality randomized trials have produced mixed results: some have shown that testosterone worsens the apnea-hypopnea index in older, obese, or at-risk men, while others in broader populations have not found a clinically meaningful effect. The FDA labeling for approved testosterone products lists sleep apnea exacerbation as a warning, and the 2018 Endocrine Society clinical practice guideline (Bhasin et al.) lists untreated severe obstructive sleep apnea (OSA) as a condition where testosterone therapy should be initiated with caution.

The practical read most prescribers work from is that treated, well-controlled OSA is not a reason to avoid TRT, but untreated OSA or new-onset symptoms on therapy are a reason to pause, screen, and stabilize the airway disease first. Men with both conditions also need closer monitoring of hematocrit and cardiovascular markers because the two problems compound each other.

For the broader context on TRT side effects, start with our side effects pillar guide. For a look at the cardiovascular safety data most commonly referenced alongside OSA, see our breakdown of the TRAVERSE trial.

What obstructive sleep apnea actually is

Obstructive sleep apnea is a disorder in which the upper airway repeatedly collapses or narrows during sleep, causing partial (hypopnea) or complete (apnea) breathing cessation. Each event lowers blood oxygen and triggers a brief arousal as the brain forces the airway back open. A typical moderate-to-severe case involves dozens of events per hour, night after night.

The severity metric most clinicians use is the apnea-hypopnea index (AHI), expressed as events per hour of sleep:

• Normal: AHI < 5
• Mild OSA: AHI 5-14
• Moderate OSA: AHI 15-29
• Severe OSA: AHI ≥ 30

OSA is common in exactly the population most likely to be evaluated for TRT. Peppard et al. (American Journal of Epidemiology, 2013), a landmark prevalence study, estimated that roughly 26% of American adults aged 30-70 have at least mild sleep-disordered breathing and that prevalence rises sharply with age and body mass. The overlap with hypogonadism evaluation is substantial.

OSA is also not neutral. Over years, it is associated with hypertension, atrial fibrillation, stroke, daytime cognitive impairment, metabolic dysfunction, and mood disturbance. Many of the symptoms that send men in for a testosterone workup — fatigue, low libido, poor concentration, weight gain — can also be explained by untreated OSA. Untangling which is which is a core part of a competent low-T workup.

How testosterone could worsen sleep apnea

The biological mechanisms linking testosterone to OSA risk are plausible but not perfectly settled. Three pathways are most often discussed in the peer-reviewed literature:

1. Upper-airway anatomy and tone. Testosterone may subtly influence pharyngeal soft tissue volume and muscle tone. A more collapsible airway is more prone to obstruction during sleep, particularly in REM when pharyngeal muscle tone is physiologically lowest.
2. Ventilatory control (loop gain).Testosterone has been proposed to influence the chemoreceptor response to CO2 and the brain's ventilatory drive. Higher "loop gain" — an overshoot-and-undershoot pattern in breathing response to hypoxia — destabilizes breathing during sleep and can increase AHI.
3. Fluid shift and rostral fluid redistribution. In men with cardiovascular or renal compromise, testosterone-associated changes in fluid and sodium handling can worsen overnight rostral fluid shift, increasing pharyngeal wall edema and collapsibility.

None of these are deterministic. They explain why the signal is biologically plausible and why certain men respond differently than others. They do not mean that TRT reliably causes OSA in most men.

What the clinical trials actually show

The randomized trial evidence is not large, and the studies that exist vary in their population, dose, duration, and outcome measure. A fair summary of the body of research:

Hoyos et al. 2012 (Clinical Endocrinology)

A randomized, double-blind, placebo-controlled trial in 67 men with obesity and moderate-to-severe OSA, assigned to intramuscular testosterone undecanoate or placebo for 18 weeks. The testosterone group had a transient worsening of the oxygen desaturation index (ODI) at 7 weeks that was no longer significantly different from placebo at 18 weeks. The study is most often cited as evidence that testosterone can transiently worsen sleep-disordered breathing in this population, particularly early in therapy.

Liu et al. 2003 (Journal of Clinical Endocrinology & Metabolism)

A crossover study in older men examining the dose-response of exogenous testosterone on breathing during sleep. Higher doses showed a signal for worsened sleep breathing. This is the most commonly referenced older work on the dose-response question.

Killick et al. 2013 (Clinical Endocrinology)

An extension analysis of obese men with OSA treated with testosterone, which reinforced that the early worsening Hoyos identified largely resolved over longer treatment, suggesting adaptation or confounding by weight change during the trial.

Snyder et al. 2016 (New England Journal of Medicine) — Testosterone Trials

The Testosterone Trials were a coordinated set of NIH-funded placebo-controlled trials in 790 men aged 65 or older with low testosterone. They evaluated sexual function, physical function, vitality, cognition, anemia, bone density, and cardiovascular endpoints. Sleep apnea was not a primary endpoint in these trials, but the safety profile did not raise a prominent OSA signal in the population studied. The trials' 1-year duration and exclusion criteria limit what they can say about men with pre-existing severe OSA.

Meta-analyses

Multiple meta-analyses through the 2010s and early 2020s have pooled the available OSA outcome data from testosterone trials. The general pattern is a small, non-consistent effect on AHI, with heterogeneity driven by baseline OSA severity, obesity, age, and delivery method. This is one reason the guideline language uses words like "caution" and "monitor" rather than "contraindicated."

Visualizing the evidence base

The conceptual chart below summarizes the rough direction of AHI change reported across several representative studies. Numbers are approximate, drawn from published summaries and pooled estimates, and are meant to convey the pattern in the literature — not a single definitive number.

The aggregate read is that testosterone does not reliably or dramatically worsen the apnea-hypopnea index in unselected men, but it can transiently or modestly worsen it in men with obesity and pre-existing OSA, particularly early in therapy. Delivery method, dose, and whether OSA is treated at baseline are meaningful moderators.

TRAVERSE 2023 and the sleep apnea signal

TRAVERSE (Lincoff et al., New England Journal of Medicine, 2023) is the largest contemporary randomized trial of testosterone therapy. It enrolled 5,246 men aged 45-80 with symptomatic hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk. Men were randomized to transdermal testosterone gel or placebo and followed for a mean of about 33 months, with the primary endpoint being major adverse cardiovascular events (MACE).

On the primary MACE endpoint, testosterone met the pre-specified non-inferiority threshold versus placebo. But the trial also reported several numerically imbalanced secondary and safety events in the testosterone arm, including pulmonary embolism, atrial fibrillation, acute kidney injury, and nephrolithiasis. Sleep apnea events were also reported in the trial's adverse-event tracking.

Important caveats for interpreting TRAVERSE on the OSA question:

• TRAVERSE used transdermal testosterone gel, which produces smaller peak testosterone excursions than injection protocols that are more commonly used in community TRT practice.
• TRAVERSE was not designed as a sleep apnea trial. Sleep-disordered breathing was not measured with polysomnography in all participants, so the trial is underpowered for AHI outcomes.
• The enrolled population was older and had pre-existing cardiovascular disease, which limits generalization to younger men.

For a full breakdown of TRAVERSE, see our companion article on what the TRAVERSE trial actually says. For context on the related hematocrit findings, which interact with OSA physiology, see hematocrit on TRT.

Who is at highest risk

Not every man on TRT faces the same OSA risk. Stratification matters. The men most commonly flagged as higher-risk for sleep-apnea-related complications on testosterone therapy share a recognizable profile:

• Obesity, especially central obesity (BMI ≥ 30, neck circumference > 17 inches in men)
• Pre-existing, undiagnosed, or undertreated OSA
• Loud habitual snoring with witnessed apneas
• Hypertension that is poorly controlled or drug-resistant
• Heart failure or atrial fibrillation history
• Anatomic risk factors: retrognathia, crowded oropharynx, nasal obstruction
• Heavy alcohol use or chronic benzodiazepine/opioid use
• Men on injection-based TRT with higher peaks, particularly every-two-week cypionate/enanthate

If several of these apply to you, a prudent prescriber is likely to screen more aggressively and to consider a sleep study before or shortly after starting TRT.

A profile comparison, visualized

The chart below is a simple radar illustration of the typical risk profile difference between a low-risk and higher-risk TRT candidate on the variables most relevant to OSA. It is conceptual and not a diagnostic tool.

Screening before and during TRT

Universal polysomnography for every TRT candidate is not standard of care. Targeted screening is. Most competent prescribers use a two-step approach: a validated symptom questionnaire followed by a sleep study when the questionnaire flags meaningful probability.

STOP-BANG: the most common quick screen

STOP-BANG (Chung et al., Anesthesiology, 2008; subsequently validated broadly) is an eight-question screening tool for obstructive sleep apnea that a prescriber can run in under two minutes. It asks about Snoring, Tiredness, Observed apneas, blood Pressure, BMI, Age, Neck circumference, and Gender. Each "yes" is one point.

• 0-2 points: low risk of OSA
• 3-4 points: intermediate risk
• 5-8 points: high risk

Epworth Sleepiness Scale

The Epworth Sleepiness Scale captures subjective daytime sleepiness. It is not specific to OSA — it catches daytime sleepiness from many causes — but a score of 11 or above is often used to prompt further evaluation.

Sleep study options

When screening suggests intermediate or high probability, the definitive tools are:

• In-lab polysomnography. The gold standard. Measures AHI, oxygen saturation, sleep stages, and arousal index.
• Home sleep apnea test (HSAT). A simplified overnight recording performed at home. Validated for uncomplicated adult OSA diagnosis; less sensitive in complex cases or when comorbidities complicate interpretation.

Ongoing screening on therapy

Screening is not only a pre-TRT exercise. Men can develop OSA over time — weight gain, aging, and hormone change can all contribute. Re-screening with a validated questionnaire at routine TRT follow-ups is a reasonable practice. New partner complaints about snoring, new daytime sleepiness, new morning headaches, or a rising hematocrit trend that is not explained by dose are all prompts to re-screen. Our hematocrit on TRT article covers the hematocrit side of that workup.

CPAP and TRT: how they interact

Continuous positive airway pressure (CPAP) is the first-line treatment for moderate-to-severe OSA. It works by splinting the upper airway open with pressurized air delivered through a mask during sleep. For men with OSA who are starting or continuing TRT, CPAP is usually not an obstacle — it is part of the plan.

CPAP adherence matters more than TRT dose adjustments

In clinical practice, the single most impactful lever for a man with OSA on TRT is CPAP adherence — consistent nightly use for the full sleep period. Poor CPAP adherence leaves the underlying airway disease untreated, and the risks of TRT in that setting are essentially the risks of untreated OSA compounded by the modest physiologic effects of testosterone.

Effect of CPAP on endogenous testosterone

Observational data, including work by Hoyos et al. and others, suggest that treating OSA with consistent CPAP modestly raises endogenous testosterone in some men. The effect is not dramatic — often a small, variable improvement — but it is part of why sleep apnea treatment is considered foundational for men with suspected low T before jumping to exogenous therapy. See our guide to natural testosterone optimization for more on the sleep-testosterone relationship.

Effect of CPAP on TRT pharmacokinetics

CPAP does not meaningfully change how injected or transdermal testosterone is absorbed or cleared. Dose changes are not required just because a patient starts CPAP.

CPAP and hematocrit

Untreated OSA is itself a cause of secondary erythrocytosis because chronic intermittent hypoxia drives erythropoietin production. Adding testosterone to an unventilated hypoxic system compounds that signal. Treating OSA with CPAP lowers nocturnal hypoxia and often eases the hematocrit picture. This is why many TRT-literate prescribers will push hard on CPAP adherence before considering therapeutic phlebotomy in a man with both conditions.

What guidelines recommend

The practice-guideline landscape on TRT and sleep apnea is reasonably consistent across major bodies, even as research continues to evolve.

Endocrine Society (Bhasin et al., 2018)

The 2018 Endocrine Society clinical practice guideline on testosterone therapy lists untreated severe OSA among the conditions in which testosterone therapy should be initiated with caution. The guideline does not list treated OSA as a contraindication. It emphasizes clinical judgment, evaluation of severity, and reassessment if symptoms emerge on therapy.

AUA (2018 guideline, updated 2024)

The American Urological Association's guideline on the evaluation and management of testosterone deficiency (Mulhall et al., 2018; updated 2024) similarly treats OSA as a condition requiring clinical consideration rather than an absolute contraindication. It highlights the importance of patient education about the potential for sleep apnea exacerbation and the need for monitoring.

FDA product labeling

FDA-approved testosterone product labels — across major brand and generic formulations — include warnings that testosterone may cause or exacerbate sleep apnea, particularly in men with risk factors such as obesity or chronic lung disease. The exact wording varies slightly by product but the warning is essentially universal.

AASM (American Academy of Sleep Medicine)

AASM clinical practice parameters for OSA treatment focus on the standard management of sleep apnea itself — positive airway pressure, oral appliances, weight reduction, and, in select cases, surgery. They do not prescribe testosterone protocols, but they reinforce that OSA should be adequately managed in any patient for whom it is diagnosed, independent of TRT considerations.

Summary table of guideline positions

What to do if you suspect sleep apnea on TRT

Men sometimes notice new or worsening sleep-related symptoms after starting TRT. The most useful framework for what to do with that observation is structured around escalation, not panic.

Symptoms that should prompt a conversation with your prescriber

1. New or louder snoring reported by a bed partner
2. Witnessed apneas or gasping/choking at night
3. Daytime sleepiness that is new, or an Epworth score of 11+
4. Morning headaches, dry mouth, or non-restorative sleep
5. New or worsening hypertension, particularly early-morning readings
6. Rising hematocrit beyond what the dose alone explains
7. New atrial fibrillation or unexplained palpitations

A realistic scenario

A 49-year-old man with a BMI of 31, starting intramuscular testosterone cypionate 160 mg weekly, reports at his 3-month follow-up that his wife has been complaining about louder snoring since he started TRT, he is more tired in the afternoon, and his hematocrit has climbed from 46% to 53%. His prescriber refers him for a home sleep apnea test, which shows AHI 22 with an oxygen nadir of 82%. The patient is started on CPAP with good adherence, his hematocrit settles back to 49% three months later, and his daytime energy improves. His TRT protocol remains unchanged through the process. This pattern is representative, though every case is individual.

Things not to do

• Do not stop TRT abruptly on your own based on a blog article
• Do not adjust your dose down or up without a prescriber
• Do not dismiss a partner's report of snoring or witnessed apneas as unimportant
• Do not skip CPAP "because TRT is making me feel better" — the two are independent

For men considering whether to pause or step off testosterone entirely during an OSA workup or treatment initiation, our coming off TRT article walks through what HPTA recovery typically looks like. For men weighing alternatives that do not suppress the HPTA in the same way as exogenous testosterone, see enclomiphene vs TRT and clomid vs TRT.

The honest bottom line

The relationship between TRT and sleep apnea is best described as contested, context-dependent, and manageable when the right screening, monitoring, and OSA treatment are in place. Testosterone therapy is not a blanket cause of sleep apnea, but it is also not inert for men at the extreme of the risk spectrum, and randomized trial signals have been real enough to earn an FDA warning and a cautionary paragraph in major guidelines.

For men starting TRT, the practical takeaways most often acted on in competent clinical practice are:

• Screen with a validated tool before starting, and again if symptoms change
• Treat known OSA adequately — usually with CPAP adherence — before and during therapy
• Monitor hematocrit more attentively in men with OSA
• Take a bed partner's report of new snoring or apneas seriously
• Reassess the protocol and the OSA treatment if symptoms emerge

For broader context, the side effects pillar guide is the anchor for this topic. For the monitoring of the related lab marker most affected by the OSA-TRT overlap, see hematocrit on TRT. For the cardiovascular-safety backdrop that most clinicians reason against, read our TRAVERSE trial explainer. And for an honest look at how side effects and benefits typically unfold over the first year of therapy, the TRT before and after timeline is the place to go.